Comparative Study of Human Immunodeficiency Virus Negative Host Talaromyces Between Voriconazole and Amphotericin Sequential Itraconazole Therapy

NAUnknownINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

December 30, 2018

Primary Completion Date

December 30, 2021

Study Completion Date

December 30, 2021

Conditions
Talaromyces in Human Immunodeficiency Virus NegativeTo Compare Voriconazole and Amphotericin Sequential Itraconazole TherapyTo Dynamically Monitor the Anti-Interferon-γ Autoantibodies
Interventions
DRUG

Voriconazole

"6mg/kg bid, was given on the first day, followed by intravenous 4mg/kg bid for 6 days, followed by oral Valconazole 200mg bid for at least 6 months.~Amphotericin B sequential itraconazole group (intravenous amphotericin, dose 0.7 - 1.0 mg / kg / d, 14 days, then changed oral itraconazole 200 mg bid for 10 weeks, after which 100 mg bid maintenance Until CD4+ T cells are greater than 100 cells/L for at least 6 months"

Trial Locations (1)

530021

RECRUITING

Guangxi Medical University, Nanning

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

First Affiliated Hospital of Guangxi Medical University

OTHER

collaborator

Second Affiliated Hospital of Guangzhou Medical University

OTHER

collaborator

The Fourth People's Hospital of Nanning

OTHER

collaborator

Guilin Medical College

OTHER

collaborator

Nanning Second People's Hospital

OTHER

lead

Guangxi Medical University

OTHER

NCT03827278 - Comparative Study of Human Immunodeficiency Virus Negative Host Talaromyces Between Voriconazole and Amphotericin Sequential Itraconazole Therapy | Biotech Hunter | Biotech Hunter